Research programme: neurodegenerative disorder therapeutics - Sharp Edge Labs/ Sumitomo Dainippon Pharma

Drug Profile

Research programme: neurodegenerative disorder therapeutics - Sharp Edge Labs/ Sumitomo Dainippon Pharma

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sharp Edge Labs; Sumitomo Dainippon Pharma
  • Class Small molecules
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurodegenerative disorders

Most Recent Events

  • 03 Jan 2017 Sharp Edge Labs and Sumitomo Dainippon Pharma agree to co-develop therapeutics for Neurodegenerative disorders in USA
  • 03 Jan 2017 Early research in Neurodegenerative disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top